ARCH BIOPARTNERS
Arch Biopartners Inc., a biotechnology company, focuses on acquiring and developing products and technology for sale to pharmaceutical and industrial companies. The company, through its subsidiaries, focuses on developing diagnosis and treatments for brain tumors; binding of peptides to solid surfaces; treatments for chronic kidney and bowel diseases caused by non-infectious inflammation; and anti-cancer compounds. Arch Biopartners Inc. is headquartered in Toronto, Canada.
ARCH BIOPARTNERS
Industry:
Biopharma Biotechnology Medical
Founded:
2010-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.archbiopartners.com
Total Employee:
1+
Status:
Active
Contact:
(647) 428–7031
Email Addresses:
[email protected]
Total Funding:
5.6 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag ReCAPTCHA Google Analytics 4
Similar Organizations
ADS Biosystems
ADS Biosystems research and develops solutions and methods for early cancer detection and metabolic diseases.
E-Sep Technologies
E-Sep Technologies fully demineralizes any dairy stream for production of premium food and/or pharmaceutical grade products.
Enterin
Philadelphia-based biotechnology company .
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Employees Featured
Founder
Stock Details
Investors List
National Research Council of Canada Industrial Research Assistance Program
National Research Council of Canada Industrial Research Assistance Program investment in Grant - Arch Biopartners
Canadian Institutes of Health Research
Canadian Institutes of Health Research investment in Grant - Arch Biopartners
Official Site Inspections
http://www.archbiopartners.com Semrush global rank: 9.01 M Semrush visits lastest month: 445
- Host name: 126.26.111.34.bc.googleusercontent.com
- IP address: 34.111.26.126
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arch Biopartners"
Arch Biopartners (TSXV:ARCH) Company Profile & Description
2 days ago Company profile for Arch Biopartners Inc. (TSXV:ARCH) with a description, list of executives, contact details and other key facts.See details»
Arch Biopartners - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number (647) 428–7031 Arch Biopartners Inc., a biotechnology company, focuses on acquiring and developing products and technology for …See details»
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) - LinkedIn
Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB) | 535 followers on LinkedIn. A late stage clinical trial company focused on the development of novel therapeutics targeting organ …See details»
Arch Biopartners - Overview, News & Similar companies - ZoomInfo
Aug 2, 2019 Who is Arch Biopartners. Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significa nt …See details»
Arch Biopartners - Craft
Oct 29, 2024 Arch Biopartners is a biotechnology company that develops technologies for the medical sectors. Its key platforms include MetaBlok treating, organ injury caused by …See details»
Arch Biopartners Inc. - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
Arch Biopartners Inc Company Profile | Toronto, ON, Canada ...
Find company research, competitor information, contact details & financial data for Arch Biopartners Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
About us – Arch Biopartners
The company holds a strong patent position for its two lead drug candidates LSALT peptide and Cilastatin, two DPEP1 inhibitors with the potential to play a major role preventing acute kidney …See details»
Board of Directors and Advisors – Arch Biopartners
ARCH:TSXV ACHFF:OTCQB. Menu. MenuSee details»
Arch Biopartners Arranges Non-Brokered Private Placement
TORONTO, March 05, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a …See details»
Arch BioPartners 2025 Company Profile: Stock Performance
Arch BioPartners General Information Description. Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation.See details»
Board of Directors and Advisors – Arch Biopartners
From 2010 to 2012, Mr. Smith led the Finance and Business Development organization for Region Latin America and in 2013 moved to France as CFO for France and BeLux. In 2016, …See details»
Arch Biopartners Receives Funding for Development of LSALT …
TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on …See details»
Executive Team - Arch Biopartners
Mar 5, 2019 For the past 9 years, Mr. Bishop has also served as a Director and Chair of Willow Breast & Hereditary Cancer Support, a not-for-profit organization focused on breast and …See details»
Investor Information – Arch Biopartners
[email protected]. Mailing Address. 545 King St W. Toronto, Ontario Canada M5V 1M1. Reports and Filings. See the Reports and Filings section on our website. Sedar Profile. View …See details»
Our Science – Arch Biopartners
A new mechanism of action A drug platform to inhibit DPEP1. In March 2024 Arch lead scientists published an article in the British Medical Journal Open (BMJ Open).The Phase II findings in …See details»
Arch Biopartners, Inc. (Arch Biopartners, Inc.) - 药物管线_专利_临床 …
了解Arch Biopartners, Inc. (Arch Biopartners, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 31篇新闻，疾病领域:神经系统疾病，肿瘤，感染，技术平台:小分子化药，其 …See details»
Arch Biopartners (TSXV:ARCH) Stock Price & Overview - Stock …
Financial Performance. In 2024, Arch Biopartners's revenue was 2.12 million, an increase of 6.97% compared to the previous year's 1.98 million. Losses were -3.92 million, 17.8% more …See details»
Press Releases – Arch Biopartners
TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed a non …See details»
Landmark Bio Acquired by Artis BioSolutions to Expand …
2 days ago The organization was established by leaders from academia, industry, and Boston's leading research hospitals. Together with Artis BioSolutions, Landmark Bio will enhance its …See details»